Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
92.73
-5.34 (-5.45%)
At close: Feb 27, 2026, 4:00 PM EST
92.66
-0.07 (-0.08%)
After-hours: Feb 27, 2026, 7:32 PM EST
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 283 employees as of December 31, 2024. The number of employees increased by 57 or 25.22% compared to the previous year.
Employees
283
Change (1Y)
57
Growth (1Y)
25.22%
Revenue / Employee
$670,519
Profits / Employee
-$713,488
Market Cap
6.23B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | 90 | 20 | 28.57% |
| Mar 31, 2020 | 70 | 7 | 11.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| CRISPR Therapeutics AG | 393 |
| Immunovant | 362 |
| Mirum Pharmaceuticals | 355 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 225 |
| Arcellx | 163 |
RYTM News
- 1 day ago - Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - GlobeNewsWire
- 8 days ago - Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market - Benzinga
- 10 days ago - Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - GlobeNewsWire
- 22 days ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - GlobeNewsWire
- 7 weeks ago - Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - GlobeNewsWire
- 2 months ago - Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript - Seeking Alpha